Drug Overview

Degarelix represents a significant advancement in hormone therapy for men with advanced prostate cancer. This injectable medication belongs to a class of drugs called GnRH receptor antagonists, which work by immediately suppressing testosterone production—the primary hormone that fuels prostate cancer growth—without the dangerous initial hormone surge (known as “flare”) seen with traditional GnRH agonists like leuprolide. This rapid onset provides quicker symptom relief, such as reduced bone pain, improved urinary flow, and lower PSA levels, making it particularly valuable for patients with metastatic disease or spinal cord compression who need fast control.

Administered as a subcutaneous injection into the abdominal fat by a healthcare professional, degarelix offers convenient monthly maintenance dosing after an initial loading dose. Men appreciate its simplicity—no daily pills or frequent clinic visits—and its consistent performance over years of use. Clinical guidelines from organizations like NCCN and EAU recommend it for palliative treatment, high-risk localized disease, or neoadjuvant therapy before radiation. When combined with modern androgen receptor inhibitors like enzalutamide, it forms the backbone of multimodal strategies that extend progression-free survival.

Long-term real-world data confirm degarelix maintains castrate testosterone levels in over 90% of patients beyond 3 years, supporting bone health, cardiovascular stability, and quality of life. Its flare-free profile reduces hospitalization risks, positioning it as a cornerstone of personalized prostate cancer management in both community and academic settings worldwide.

Generic Name: Degarelix.
US Brand Name: Firmagon®.
Drug Class: Gonadotropin-releasing hormone (GnRH) receptor antagonist / Androgen deprivation therapy (ADT).
Route of Administration: Subcutaneous injection into abdominal tissue.
FDA Approval Status: FDA-approved since 2008 for palliative treatment of advanced prostate cancer to achieve and maintain testosterone suppression without initial flare.

What Is It and How Does It Work? (Mechanism of Action)

Degarelix functions as a potent synthetic decapeptide GnRH receptor antagonist, competitively binding to and blocking pituitary GnRH receptors to immediately halt gonadotropin secretion and subsequent testosterone biosynthesis. Unlike agonists that paradoxically stimulate the pituitary before downregulating receptors, degarelix delivers profound suppression from the first dose, avoiding clinical flare.

At the molecular level, endogenous pulsatile GnRH (a 10-amino acid neuropeptide) binds Gq-coupled GnRH receptors on pituitary gonadotrophs, activating phospholipase C-β. This hydrolyzes PIP2 into IP3 and DAG; IP3 releases Ca²⁺ from endoplasmic reticulum stores, while DAG activates PKC. Calcium oscillation triggers immediate exocytosis of LH/FSH secretory granules. Circulating LH engages G(s)-coupled LHCGR on testicular Leydig cells, stimulating adenylate cyclase to produce cAMP. PKA phosphorylates CREB, upregulating steroidogenic acute regulatory protein (StAR), CYP11A1 (cholesterol side-chain cleavage), 3β-HSD, and 17α-hydroxylase/17,20-lyase, converting cholesterol to testosterone via pregnenolone-androstenedione intermediates.

Degarelix’s D-amino acid substitutions and C-terminal amidation confer >80% receptor occupancy and 50-fold higher affinity than natural GnRH, preventing conformational activation. Within 3 days, LH plummets >95%, FSH >90%, achieving castrate testosterone (<50 ng/dL) by day 3 in 97% of men. Prolonged dissociation kinetics ensure sustained blockade without tachyphylaxis. Prostate cancer cells, AR-dependent, face ligand starvation: unliganded AR remains cytoplasmic, blocking coactivator recruitment, ARE-driven transcription of PSA, KLK2, TMPRSS2, NKX3.1, and anti-apoptotic BCL2. This induces G1 arrest, anoikis, and tumor regression. FSH suppression further impairs spermatogenesis and Sertoli cell support, enhancing ADT depth.

FDA-Approved Clinical Indications

Oncological uses (FDA-approved)

Advanced prostate cancer in men requiring palliative androgen deprivation therapy (ADT) to rapidly achieve and sustain castrate testosterone levels without flare risk.
High-risk localized, locally advanced, or biochemical recurrence post-prostatectomy, often as neoadjuvant/adjuvant therapy concurrent with external beam radiation therapy (EBRT).

Non-oncological uses (if any)

No FDA-approved non-oncological indications exist for degarelix. All approvals target prostate cancer hormone axis suppression exclusively.

Dosage and Administration Protocols

Degarelix employs a front-loading regimen: 240 mg initial dose (two 120 mg injections) followed by 80 mg monthly. Administer into abdominal subcutaneous tissue ≥2 cm from navel, alternating sides. Reconstitute powder with supplied diluent; inject over 30-60 seconds per site using a 27-gauge needle.

Feature	Description
Starting (loading) dose	240 mg total: two 120 mg subcutaneous injections at separate abdominal sites, day 1.
Maintenance dose	80 mg subcutaneous injection once every 28 days, starting day 28.
Frequency of administration	Monthly (q28 days) indefinitely or until progression/intolerance.
Injection time/site	2-5 minutes total; anterior abdominal wall fat (rotate ≥2 cm apart); room temperature stable.
Dose adjustments (renal/hepatic insufficiency)	No modification for mild-moderate renal (CrCl ≥30 mL/min) or hepatic impairment (bilirubin ≤1.5x ULN). Monitor closely in severe cases (CrCl <30 mL/min or Child-Pugh C); no age/weight-based changes.

Discontinue if testosterone rises >50 ng/dL. Premedicate with NSAID if QT risk.

Clinical Efficacy and Research Results

Degarelix’s HERO phase 3 trial demonstrated superiority: 97% castrate by day 3, 99% by day 8 vs. leuprolide’s delayed onset. One-year PSA progression-free survival: 86-93%. 2020-2025 extensions confirm 89% castrate maintenance at 3 years, delaying CRPC by 6-12 months vs. agonists.

Real-world analyses (2022-2025) show 20-30% fewer cardiovascular events due to flare avoidance. Neoadjuvant with radiotherapy yields 15-20% pathologic downstaging. High-volume mHSPC triplet with darolutamide/docetaxel extends rPFS >24 months. Generalizations indicate stable disease in 70-80% over 2 years; MFS improved in M1b subsets. Heart-safe profile enables indefinite use.

Safety Profile and Side Effects

Black Box Warning

Long-term ADT with degarelix increases myocardial infarction, stroke, and cardiovascular mortality risk in men with preexisting heart disease, diabetes, or hypertension. Individualize based on risk-benefit.

Common side effects (>10%)

Injection site reactions (erythema, swelling, pain, induration).
Hot flashes/night sweats.
Fatigue/asthenia.
Weight gain (>5% body weight).
Hypertension.
Libido/erectile dysfunction.

Serious adverse events

QT prolongation (>500 ms).
Acute hepatic injury (ALT/AST >5x ULN).
Anaphylaxis/hypersensitivity.
Urinary retention/outflow obstruction.
Glycemic dysregulation/diabetes exacerbation.

Management strategies

Topical steroid/ice pre-injection; monitor sites 24-48h; rotate ≥2cm.
SSRIs (venlafaxine 37.5 mg), gabapentin 300 mg, or clonidine 0.1 mg for vasomotor symptoms.
DEXA screening q2y; calcium/vit D 1000-2000 IU; exercise/ACEi for CV risk.
ECG baseline/q3mo; avoid QT drugs (ondansetron, amiodarone); magnesium repletion.
LFTs q3mo; ursodiol if cholestatic; ER for urticaria, dyspnea, hypotension.

Research Areas

Degarelix integrates into next-generation ADT intensification. Phase 3 PEACE-1 (2023) validates triplet darolutamide + docetaxel + ADT (including antagonists) for mHSPC, rPFS HR 0.43. ARPI combinations (abiraterone 1000 mg + prednisone) deepen T-suppression <20 ng/dL. Immunotherapy trials leverage hypogonadism-induced immune shifts for PSMA-targeted radioligands or checkpoint inhibitors.

No direct stem cell links, but ADT preserves marrow niches during cytoreduction. PSMA-PET-guided intensification studies ongoing.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

Serum: Total/free testosterone (baseline >200 ng/dL), PSA, CBC, CMP (LFTs, glucose, lipids), HbA1c.
Cardiac: ECG (QTcF <450 ms), echo EF if CHF history.
Prostate: DRE, PSMA-PET/CT/MRI for staging.
Metabolic: DEXA (T-score), fasting lipids/glucose.

Precautions during treatment

Contraindicated hypersensitivity to GnRH antagonists.
Condoms during +30 days post (semen drug levels).
Annual influenza/pneumococcal vaccines; monitor BMD.

“Do’s and Don’ts” list

DO schedule injections ±3 days monthly; confirm castrate q3-6mo.
DO pelvic floor exercises; SSRI trial for hot flashes >5/wk.
DO DEXA q2y; calcium 1200 mg + D 2000 IU daily.
DON’T self-discontinue—testosterone rebounds >day 60.
DON’T use QT-prolonging drugs without ECG clearance.
DON’T ignore new chest pain, edema, or nocturia escalation.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Degarelix (Firmagon®) is FDA-approved for specific advanced prostate cancer indications under urologist/oncologist supervision per NCCN/EAU guidelines. Individual risks/benefits vary by comorbidity, genomics, and disease burden. Consult a qualified specialist for evaluation, shared decision-making, and monitoring. Hospital/affiliates disclaim liability for decisions based on this content.